Try our Advanced Search for more refined results
Life Sciences - January, 2015
323 articles
- Bayer Settles Workers' $100M Sex Discrimination Suit
- CVS Accuses Former Director Of Stealing Trade Secrets
- FTC Orders Divestitures In $4B Sun-Ranbaxy Pharma Merger
- Latham's Shake Shack IPO Grabs Spotlight Amid Busy Week
- Philips Gets Nod To Pursue Infringement Claims Against Zoll
- Some Insurers Use Drug Prices To Discriminate, Report Says
- Risperdal Judge Warns J&J Over Introducing FDA Docs
- Medicis Can't Duck Acne Med Suit Under Intermediary Doctrine
- Abbott Labs Escapes Class Cert. Bid By Ensure Drinkers
- SEC Dismisses Herbalife Insider Trading Case
- FDA Accused Of Helping J&J Cover Up Risperdal Data
- Spark Therapeutics Soars After Raising $161M In Upsized IPO
- Valeant Eyes $296M Prostate Drug In 1st Post-Allergan Play
- Thoughts On Consolidating Federal And State Antitrust Cases
- A General Counsel's Top 10 Tips On Calif. Wage-And-Hour Law
- FTC's Provigil Pay-For-Delay Suit Passes Actavis Test: Judge
- Tylenol Liver-Damage MDL Bellwether Gets June Trial Date
- J&J Tried To Obscure Risperdal Risks, Ex-FDA Chief Says
- Brown Rudnick Gets Partial Win In Malpractice Fight
- Immunomedics Sidesteps Securities Fraud Suit
- Quest Diagnostics Accused Of Building Calif. Monopoly
- VC-Backed Flex Pharma Stumbles After Pricing Upsized IPO
- GSK's Ebola Vaccine Shows Promise In First Trial
- Chinese Law Key To Vitamin Antitrust Case, 2nd Circ. Hears
- False DaVita Testimony Jeopardizing Privilege In FCA Suit
- Gibson Dunn Nabs Ex-King & Spalding FDA Regulatory Partner
- January Brings Clarity To Some Of 2014's Buzziest M&A Moves
- Omeros Looks To Raise $80M In Follow-On Offering
- Nixon Peabody, Mintz Levin Using Barred Defense, Court Told
- Expert Testimony Falls Short In Fixodent MDL, Judge Says
- Key Questions When Selecting E-Discovery Vendors
- 2nd Circ. To Weigh Chinese Gov't Role In Vitamin C Appeal
- Cancer Biotech Kolltan Pharmaceuticals Pulls $86M IPO
- 6th Circ. Yanks Payments To 2nd-Priority Dow Implant Victims
- EU OKs $23B Novartis, GlaxoSmithKline 3-Part Deal
- FDA Boosts Defibrillator Oversight After Device Failures
- Ex-FDA Chief Says J&J Knew Adolescent Risperdal Risks
- Fraud Suits Targeting Sanofi Over MS Drug Prospects Tossed
- HHS Asks DC Court To Nix PhRMA's 340B Orphan Drug Suit
- Atara Joins Flood Of Life Science Cos. Tapping Market
- Product Liability Trials To Watch In 2015
- Medtronic Unit Gets Another Bosch Telehealth Patent Nixed
- Hagens Berman Didn't Verify Thalidomide Claim, Court Told
- Growth Hormone Biotech Ascendis Raises $108M In IPO
- Kirkland Steers Traditional Chinese Med. Co. In $1.34B Buy
- VC-Backed Spark Therapeutics Boosts IPO Target To $157M
- Reflections On The Remarkable Rise Of Orphan Drugs
- Takeaways From Indian Court Ruling In Symed V. Glenmark
- Effexor Plaintiffs Want To Drop 40% Of Suits From MDL
- And Now A Word From The Panel: 2014 JPML Practice Trends
- Sandoz, Mylan Lose Bid For Speedy Copaxone Remand
- House GOP Unveils Sweeping FDA Overhaul
- J&J, Bristol-Myers Get AWP Claims Nixed In Pa. Court
- Investment Firms Sue Merck Over Misleading Vioxx Claims
- Wis. AG, Novartis Settle Wholesale Drug Pricing Dispute
- McDermott Snags Health IT Pro From Mintz Levin
- Boehringer, Amneal Strike Deal To End Aggrenox Patent Row
- Silicon Valley Bank Parent Prices $350M In Senior Notes
- Pfizer Strikes $400M Deal To End Shareholder Suit
- Forest Labs Blasts Bid To Expand Class in Sex Bias Suit
- House Panel Takes Up DEA Drug Approval, Enforcement Bills
- Myriad Settles Breast Cancer Test Patent Suit With Ambry
- Zosano's $50M IPO Kicks Off 9 Expected Life Science Debuts
- FDA Policy On Wellness Products Is Healthy For Industry
- New Medical Marijuana Plan Sparked In Pa.
- Ranbaxy, AstraZeneca Say Pay-For-Delay Deal Is Not Unlawful
- IP Firm Can't Dodge Med. Device Co.'s Malpractice Claims
- Muscle Milk Nutrition Claims Are Lean On Facts, Class Says
- An Early Test Of Antitrust Ramifications Of FDA's REMS
- Big Firms Got A Break From Securities Class Actions In 2014
- SAC Victims' Fund OK'd In $602M Insider Trading Deal
- FDA Backs Teva's Generic Nexium In Blow To Ranbaxy
- Tussle Erupts At High Court Over Teva Copaxone Suit Remand
- AIA Reviews Are A Game-Changer For Pharma, Survey Shows
- J&J Didn't Warn Of Risperdal Breast-Growth Risk, Jury Told
- Justices Remand 3 Cases Following Claim Construction Ruling
- Sandoz Says Amgen Biosimilar Claims Conflict With ACA
- FDA Taps Duke Research Expert To Head Drug, Tobacco Unit
- FDA Approves 1st-Ever Glucose Monitoring Apps
- Expert In Zoloft MDL Was Properly Excluded, Judge Says
- McDonnell Remains Free Pending 4th Circ. Appeal
- King & Spalding Lures 2 Enviro Partners From Kirkland & Ellis
- Myriad Settles Cancer Test Patent Suits With 3 Defendants
- The Future Of UK Pharmaceutical Best Practices
- BMS Asks High Court To Review Hepatitis Drug Patent Row
- With Irish Court's OK, Medtronic Completes $50B Inversion
- Insurer Off Hook For Suits Claiming Supplement Is Like Meth
- Nexium Ruling Offers Road Map For Pay-For-Delay Classes
- Human Egg Donors Near Cert. Of Antitrust Class In Pay Row
- Effexor Buyers To Join 3rd Circ. Appeal Against Wyeth, Teva
- J&J's Risperdal Caused Boy's Breast Growth, Philly Jury Told
- 2 IPOs Raise $375M As Slew Of Others Prepare Debuts
- Stanford Says PTAB Wrong To Nix Prenatal Testing Patent
- Economists, Docs Back Actavis In Namenda Injunction Row
- 9th Circ. Flips Kimberly-Clark Unit's Pain Pump Win
- Generic Drug Cos. Face Failure-To-Warn Claims In Calif.
- 3 More Biotech Cos. Set IPO Terms Amid Flurry Of Activity
- J&J Fraud Claims Fall Flat In Mesh MDL, Plaintiffs Attys Say
- Medtronic Can Withhold Trade Secrets At $561M IRS Trial
- Top 5 Developments In Reverse Payments Over The Last Year
- Mylan Wrings Another $13.7M From GSK In Generic Paxil Row
- Fed. Circ. Told Only It Can Hear Patent Interference Appeal
- 1st Circ. OKs Class Cert. In Nexium Pay-For-Delay Suit
- A Data Security Checklist For Companies Hiring Law Firms
- Astellas Strikes $98M Deal In Prograf Antitrust MDL
- High Court ACA Subsidy Case Could Unravel Health Reform
- Novartis Wins FDA Approval For Novel Psoriasis Drug
- Venture-Backed Inotek Targets $100M In IPO, Note Offering
- FTC Stays Tough On Health Software, Even As FDA Eases Up
- Pot Dispenser Co. Faces Suit Over Fraudulent Finances
- Wal-Mart Can't Duck False Ad Suit Over Heart Supplement
- LabCorp Launches $2.9B Notes Offering To Back Covance Deal
- Plaintiffs Pick Test Case In Zimmer Knee Implant MDL
- Judge Selects 6 Bellwether Contenders In Vaginal Sling MDL
- Minority Powerbrokers Q&A: Dykema's Sherrie Farrell
- Medtronic Deal Highlights FTC Focus On Future Competition
- New Considerations For File Wrapper Estoppel
- IntenseX Falsely Touted As Sex-Enhancing Pill, Suit Says
- J&J Makes Final Trial Push Over Failed $21B Guidant Merger
- Pfizer Schemed To Block Celebrex Generics, New Suit Says
- Refusal To Nix Mylan IP Suit Causes Split Among Del. Judges
- What Legal Departments Can Expect If Buying Into E-Billing
- Pfizer Unit Can't Force Actavis To Alter Generic Drug Label
- Patent-Eligibility Guidelines Too Restrictive, USPTO Told
- FDA's Eased Oversight Is Good Omen For Health IT
- Life Sciences Cos. Eye $1.5B Through Follow-On Offerings
- In Wake Of Merger Vote, Covidien Loses Lawyer To Hologic
- Cos. Say Rival Got Confidential Docs In Diabetes Drug MDL
- High Court Urged To Review Damages Ruling In $5M IP Row
- Minority Powerbrokers Q&A: Baker Botts' Alex Bourelly
- Jury's $2M Verdict In Bard Mesh Bellwether Stands
- How High Court Teva Ruling Will Affect Patent Litigants
- Confusion Persists Over Medical Marijuana Enforcement
- Philly Xarelto Suits Combined Into Mass Tort Program
- FCPA Trends From The Last 6 Months
- Life Sciences Group Of The Year: White & Case
- Astellas Nears Settlement In Prograf Antitrust Row
- High Court Snub To Teva Labeling Case Puts Focus On FDA
- High Court Claim Construction Ruling Set To Spur New Fights
- Judge Stands By FDA's Approval Of Gout Drug
- La. Wins Remand Of Fresenius Suit In Dialysis Drug MDL
- Biz Profs Back Actavis In NY AG Antitrust Injunction Fight
- Actos Was Pa. Man's Biggest Bladder Cancer Risk, Expert Says
- Lawyers Weigh In On High Court Claim Construction Ruling
- High Court Lets Teva Drug Labeling Suit Go Ahead
- Deals Rumor Mill: Hillhouse, Orbitz, Salix Pharmaceuticals
- Attys Spar Over Protections For Watchdog Employees In NJ
- Spark Eyes $108M IPO As Slew Of Life Science Cos. Set Terms
- J&J Unit Settles 111 Suits In ObTape Vaginal Sling MDL
- 3 In-House Management Strategies For 2015
- Arthrex Can't Nix Jury's $29M Patent Verdict In Fed. Circ.
- Supreme Court Won't Hear Appeal Over Ohio Landfill Cleanup
- FTC Finalizes Novartis Nicotine Patch Divestiture Deal
- Suboxone Buyers Urge Court Against Reckitt's Recon Bid
- Judge Doubts Jurisdiction In Mouthwash Suit
- Europe Plunks $115M Into J&J Ebola Vaccine Research
- FCA Fines Reckitt Benckiser Over Exec Trading Disclosures
- High Court Orders Claim Construction Deference
- Top 5 Software-Patenting Issues For Life Science Companies
- Boston Scientific, Plaintiffs Spar On Mesh MDL Experts
- Medtronic Unit Gets Bosch Telehealth Patents Nixed By PTAB
- 5th Circ. Won't Give Jailed Fen-Phen Atty New Hearing
- Drug Developer Lays Out Terms For $87M IPO
- Market Rumors: Azul, Taikang Life, GlaxoSmithKline
- FDA Unveils New Low-Risk Medical Device Guidance
- Life Sciences Group Of The Year: Sullivan & Cromwell
- Taxation With Representation: Davis Polk, Cravath, Alston
- Promega, Life Tech Both Urge Fed. Circ. To Review IP Ruling
- Baker Botts Reps Depomed In $1B J&J Unit Drug Rights Deal
- Effexor Buyers To Take Antitrust Suit To 3rd Circ.
- Roche Caps $2B Week With French Drug Co. Buy
- De Novo Review Of Claim Construction: 5 Pros, 5 Cons
- Novartis Should Win In Aredia Osteonecrosis Suit: Judge
- PharmAthene Gets $195M In Final Judgment On SIGA Fight
- Life Sciences Group Of the Year: Skadden
- FDA Says Dozens Given Nonsterile Simulated Saline
- Fed. Circ. Says IP Malpractice Suit Belongs In State Court
- Firms Take $72M Bayer MDL Fee-Shifting Fight To High Court
- Expert Links Actos To Bladder Cancer In Philly Trial
- FDA Downplays 2014 Lull In Drug Promo Discipline
- Valeant Launches $1B Private Senior Notes Offering
- Fight Over Jurisdiction Revived In Case Of Facebook Post
- Becton Wins Partial Stay Of Injunction In $340M Antitrust Suit
- CMS Vows Less Mess In New Round Of Open Payments
- Wyeth, Alaven Dodge Generic Reglan Suit
- Darwin Must Pay $8.7M To Cover Millennium False-Ad Suits
- Pharmacy Tells Texas Justices It's A Health Care Provider
- 23andMe Clients Can't Arbitrate False Ad Claims As Class
- Life Sciences Group Of The Year: Morgan Lewis
- Actos Caused Consumer's Bladder Cancer, Philly Jury Hears
- CORRECTED: PTAB Nixes Biz Method Review Of Jazz Drug Patents
- Deals Rumor Mill: Boehringer, TI Automotive, TransDigm
- Women Asked To Lie To Join Pelvic Mesh MDL, J&J Claims
- FDA Clears First-Ever Anti-Obesity 'Pacemaker'
- Trustee Objects To Device Maker's Supply Agreement
- Hatch Introduces Senate Bill To Repeal Medical Device Tax
- Minority Powerbrokers Q&A: Sterne Kessler's Dr. Longsworth
- Bellerophon Eyes $69M IPO After Spinoff From Ikaria
- Roka Slapped With Putative Class Action Over Deceptive IPO
- 2014 Health Care Enforcement Year In Review: Part 2
- 5 Important Drug And Medical Device Developments In 2014
- NY AG Stops Harm To Alzheimer's Patients — For Now
- Pfizer Dodges Asbestos Suit Over Ex-Unit's Product
- Middle Market IPOs Soar Despite Drop In Capital Raised
- Fed. Circ. Ruling Shows Appetite For Revisiting Willfulness
- Life Sciences Group Of The Year: Latham & Watkins
- Utah Bill Would Give Dying Access To Experimental Drugs
- Deals Rumor Mill: CIMB Group, Xstrata, TowerBrook
- Bard Can't Delay Upcoming Mesh Trial Over Judge's Remarks
- AstraZeneca Urges Fed. Circ. To Halt Mylan's Jurisdiction Fight
- Eisai Pushes 3rd Circ. To Revive Sanofi Antitrust Suit
- Cold Medicine Co. Can't Escape False Ad Suit
- CVS Balks At Discovery Docs In Novartis Kickbacks Suit
- Ex-Virginia Gov. McDonnell Denied Appeal Bond
- BMS, Citi, Others On Hook For $92M NJ Superfund Settlement
- Fed. Circ. Says Gore Must Pay $1B In Patent Saga
- Judge Urged To Delay Sanctions In Dental Implant IP Suit
- Stryker TCPA Class Action Sent Toward Trial
- 2014 Health Care Enforcement Year In Review: Part 1
- A Survey Of Patent Invalidations Since Alice
- High Court KBR Fight Could Lead To Endless FCA Litigation
- Actavis Urges 2nd Circ. To Toss 'Dangerous' Antitrust Order
- Hospira Joins Biosimilars Race With FDA Application
- MLB Ordered To Disclose Witness Payments In Doping Suit
- High Court Nixes Allergan Appeal Of Generic Latisse IP Case
- Supreme Court Won't Review Disbarment Of Jailed Texas Atty
- FDA Forges Ahead On Reform Of Drug Ads' Risk Disclosures
- Repeal Of Medical Device Tax Could Imperil Other ACA Taxes
- $2B Steris Inversion Could Be Delayed By Deeper FTC Probe
- Life Sciences Group Of The Year: Kaye Scholer
- Amerisource To Boost Animal Health Biz With $2.5B MWI Buy
- Roche Nabs $1B Majority In Cancer Research Co.
- Shire Inks $5.2B Deal For US Biotech NPS Pharma
- Pharmacies Face Greater Med Mal Risk In Texas Case
- Generics Makers Lose Bid To Nix Vimpat Patent In AIA Review
- Fed. Circ. Axes Merck Unit's En Banc Bid In Patent Dispute
- Life Sciences Group Of The Year: Covington & Burling
- Jones Day Seeks Oral Args Over Sanctions In Abbott Row
- Mylan Asks PTAB To Reconsider Denial Of Viread Reviews
- Ballot Initiative Could Give Ohio Voters Crack At Pot Law
- Canadian Drug Imports Could Save US Buyers Millions: Sens.
- Swedish Antitrust Officials Clear $767M ICA-Apotek Merger
- Maligned Speech-Supplement Producer Settles With FTC
- Daiichi Sankyo Pays $39M To Settle FCA Suit With Feds
- Law Schools Are (Finally) Teaching 'The Biz' Of Lawyering
- Fed. Circ. Skirts Biologics Law In Sandoz Ruling
- CytRx Board Must Face Claims It 'Spring-Loaded' Options
- Plaintiffs Can Introduce New Expert In Zoloft MDL, Judge Says
- Zurich Denied Quick Appeal In Eisai Coverage Fight
- Sens. Float Bill To Let Medicare Negotiate Drug Prices
- 5 Lessons From FDA's First Biosimilar Review
- 'Garbage' Counterclaims Claim Nixed In Androgel IP Case
- Allergan Can't Tighten Time Frame For Cancer Risk Claims
- Fed. Circ. Affirms PTAB Ruling On Hearing Device Patent
- Alder BioPharma Prices Offering At $177M
- Walgreen Escapes False Ad Suit Over Homeopathic Ear Meds
- Mylan, Abbott Offer EU Antitrust Fixes On $5.3B Inversion
- GSK, Novartis Offer EU Antitrust Fixes On $23B Deals
- Biotech Co. Xencor Sets Stage For $150M Follow-On Offering
- Judge Urged to Kill AstraZeneca, Ranbaxy Pay-For-Delay Deal
- Gilead Wins Dismissal Of Defective Drug Fraud Suit
- FTC Sues Children's Supplement Maker For False Claims
- Calif. Fixes Timing Problem For Post-Trial Motions
- 6 Industries Primed For M&A This Year
- GSK Stuck With Experts From First Abbott HIV Drug Trial
- J&J Unit Dodges Final Claims In Ortho Evra MDL
- Kean University Loses Fight Over Rights To Merck Parcel
- Vitamin Shoppe Supplement Not Organic, Suit Says
- 2nd Circuit Rules NY Can Keep Mandatory Vaccine Law
- Amgen Tries To Force Sandoz Biosimilar Disclosures
- CVS Gets FCA Claims Of Novartis Kickbacks Trimmed
- Web Postings Removal Ordered In NuScience IP Row
- Sandoz Biosimilar Clears FDA Panel In Milestone Vote
- Bard Fights To Delay Mesh Trial After Judge Urges Settling
- Kan. OKs $231M In Bonds For DHS Bio-Defense Facility
- Market Rumors: Trainline.com, Genkyotex, Dick's
- PharmAthene Gets $113M Lost Profits Award In SIGA Spat
- Mylan Asks Fed. Circ. To Mull Hatch-Waxman Jurisdiction
- House GOP Begins Assault On ACA's Medical Device Tax
- Printing Co. Exec Cops To $7M False Billing Scheme
- US Seizes $18M From NECC Owners Charged In Outbreak
- Secrets To In-House Cost Control
- 2nd Circ. OKs Quick Actavis Appeal In Namenda Antitrust Suit
- Liberty Medical Creditors Push To Sue Brass Over Pay
- Insurer Shakes BioChemic's Suit Over SEC Subpoena Claim
- Endo TCPA Suit Paused While FCC Mulls Solicited Fax Regs
- Ocular Disease-Focused Biotechs Eye Follow-On Offerings
- Alder BioPharma Eyes $124M Offering To Fund Development
- LifeNet Argues LifeCell Can't Undo $35M Patent Win
- Ex-Va. Gov. McDonnell Gets 2 Years For Corruption
- Arthrex Asks Fed. Circ. To Nix Jury's $29M Patent Verdict
- Investors Cheer $48B Medtronic Deal, Biggest Inversion Yet
- Overbroad Patent Claims May Be Challenged Earlier
- Calif. County Drug Cleanup Law Is Illegal, High Court Told
- Law360's Pay-For-Delay Cheat Sheet For 2015
- Actavis Accuses NY AG Of Trying To Slow Injunction Appeal
- Miss. AG Wins Remand Of Fresenius Suit In Dialysis Drug MDL
- Deals Rumor Mill: NPS, Morgan Stanley, Club Med
- Pfizer Nabs Majority Stake In Swiss Vaccine Manufacturer
- FDA Warns Novacap About 'Serious' Flaws At Chinese Facility
- Brazilian Officials Seek Fines In Alleged HIV Drug Cartel
- Sandoz Biosimilar Wins Support From FDA Staff
- AxelaCare Moves Into Southeast With Florida Health Co. Buy
- Bayer Asks 8th Circ. To Revisit FCA Retaliation Award
- $48B Medtronic Inversion Faces Blowback As It Heads To Vote
- Device Maker HEI Turns To Ch. 11 For Liquidation Sales
- Shifting Industry Options For Paying Physician Educators
- 12 Building Blocks Of A Digital Law Library
- Ex-Stiefel Exec. Can't Toll Stock Claims, 11th Circ. Rules
- 11th Circ. OKs Remand Of Lilly Rep's Suit To Fla. Court
- Skin Grafting Co. Sues Rival Over Pulled VA Contracts
- Aethlon Wins FDA Approval For Ebola Treatment Trials
- Life Sciences Cases To Watch In 2015
- Attys Accused Of Not Repaying $5.9M Loans For Drug Torts
- NJ Court Scraps Copayment Hikes For Public Worker Retirees
- Nexium Buyers Seek New Trial In Pay-For-Delay Case
- NY AG Says Actavis Can't Suspend Antitrust Injunction
- Life Sciences Legislation And Regulation To Watch In 2015
- GlaxoSmithKline Atty Suspended For 6 Months For M&A Work
- Jones Day Atty's Sanctions Should Be Upheld, 8th Circ. Told
- USPTO Guidelines Bring More Clarity To Patent Eligibility
- What To Expect In Criminal Antitrust This Year
- 2015: Judiciary, Lawyers And Law Schools At The Precipice